ArticleNeuroepidemiology2026
Epidemiology of Spinal Muscular Atrophy in Iceland: A Population-Based Study.
Article in Neuroepidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issuedErratum.2026
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSpinal muscular atrophy (SMA) is a hereditary neuromuscular disorder characterized by the progressive degeneration of motor neurons and the subsequent loss of muscle function. With new therapeutic options for SMA, it is important to understand the epidemiology of the disease. As of January 2024, SMA has been included in newborn screening in Iceland.
objectiveThe aim of the study was to estimate the point prevalence and incidence rate of SMA in Iceland.
methodsThis retrospective, population-based study collected data from the institutional records of the University Hospital of Iceland, pediatricians and privately practising neurologists. The incidence period was from 1997 to 2024, and the point-prevalence day was January 1st 2025. The incidence was calculated per 100,000 live births and the point prevalence per 100,000 residents.
resultsOn the prevalence day, 23 individuals had SMA in Iceland, resulting in a point prevalence of 5.9/100,000. The prevalence of SMA in children under 18 years was 10.6/100,000. During the incidence period, 17 cases of SMA were born, yielding an incidence rate of 13.9/100,000 live births. Of those born during the incidence period, twelve were alive on the prevalence day, resulting in a fatality rate of 29.4%. Two cases of SMA have been diagnosed through newborn screening since it began. DISCUSSION: The incidence and point prevalence of SMA in Iceland are high compared to those reported in other countries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.